Advanced search
Publication Cover
Journal of Dermatological Treatment Volume 34, 2023 - Issue 1
Submit an article Journal homepage
1,660
Views
0
CrossRef citations to date
0
Altmetric
Brief Report

Comparing the odds of reported depression in psoriasis patients on systemic therapy: a cross-sectional analysis of postmarketing data

Samuel YeroushalmiThe Department of Dermatology, The University of California, San Francisco, CA, USACorrespondence[email protected]
ORCID Iconhttps://orcid.org/0000-0002-8327-3279
ORCID Icon,
Mimi ChungThe Department of Dermatology, The University of California, San Francisco, CA, USA
,
Erin BartholomewThe Department of Dermatology, The University of California, San Francisco, CA, USA
,
Marwa HakimiThe Department of Dermatology, The University of California, San Francisco, CA, USA
&
John KooThe Department of Dermatology, The University of California, San Francisco, CA, USA
Article: 2152272 | Received 17 May 2022, Accepted 22 Nov 2022, Published online: 19 Jan 2023

References

  • Sahi FM, Masood A, Danawar NA, et al. Association between psoriasis and depression: a traditional review. Cureus. 2020;12(8):e9708.
  • Gautam S, Jain A, Gautam M, et al. Clinical practice guidelines for the management of depression. Indian J Psychiatry. 2017;59(Suppl 1):S34–S50.
  • Kappelmann N, Lewis G, Dantzer R, et al. Antidepressant activity of anti-cytokine treatment: a systematic review and meta-analysis of clinical trials of chronic inflammatory conditions. Mol Psychiatry. 2018;23(2):335–343.
  • Gupta M A, Vujcic B, Sheridan A D, et al. Reduced risk of suicidal behaviours associated with the treatment of hidradenitis suppurativa with tumour necrosis factor alpha antagonists: results from the US FDA adverse events reporting system pharmacovigilance database. J Eur Acad Dermatol Venereol. 2020;34(7):1564–1568.
  • Research C for DE and Questions and Answers on FDA’s Adverse Event Reporting System (FAERS). FDA. 2019. [cited 2022 Nov 8]. https://www.fda.gov/drugs/surveillance/questions-and-answers-fdas-adverse-event-reporting-system-faers.
  • Poluzzi E, Raschi E, Piccinni C, et al. Data mining techniques in pharmacovigilance: analysis of the publicly accessible FDA adverse event reporting system (AERS). In: Karahoca A, editor. Data mining applications in engineering and medicine. London: InTech; 2012.
  • Fala L. Otezla (apremilast), an oral PDE-4 inhibitor, receives FDA approval for the treatment of patients with active psoriatic arthritis and plaque psoriasis. Am Health Drug Benefits. 2015;8(Spec Feature):105–110.
  • Approved Risk Evaluation and Mitigation Strategies (REMS). [cited 2022 Apr 2]. https://www.accessdata.fda.gov/scripts/cder/rems/index.cfm?event=IndvRemsDetails.page&REMS=362.
  • Sbidian E, Chaimani A, Garcia-Doval I, et al. Systemic pharmacological treatments for chronic plaque psoriasis: a network meta‐analysis. Cochrane Database Syst Rev. 2022;5(5):CD011535.
  • The Bidirectional Relationship of Depression and Inflammation: Double Trouble - ScienceDirect. [cited 2022 May 17]. https://www.sciencedirect.com/science/article/pii/S0896627320304311.
  • Nowell WB, Karis E, Gavigan K, et al. Patient-reported nausea and fatigue related to methotrexate: a prospective, self-controlled study in the ArthritisPower® registry. Rheumatol Ther. 2022;9(1):207–221.
  • Koo J, Ho RS, Thibodeaux Q. Depression and suicidality in psoriasis and clinical studies of brodalumab: a narrative review. Cutis. 2019;104(6):361–365.
  • Papp K A, Reich K, Paul C, et al. A prospective phase III, randomized, double-blind, placebo-controlled study of brodalumab in patients with moderate-to-severe plaque psoriasis. Br J Dermatol. 2016;175(2):273–286.
  • Zerilli T, Ocheretyaner E. Apremilast (otezla): a new oral treatment for adults with psoriasis and psoriatic arthritis. P T. 2015;40(8):495–500.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.